The estimated Net Worth of Martin Vogelbaum is at least 686 千$ dollars as of 14 September 2022. Mr. Vogelbaum owns over 10,800 units of Cara Therapeutics Inc stock worth over 13,047$ and over the last 11 years he sold CARA stock worth over 320,316$. In addition, he makes 352,524$ as Lead Independent Director at Cara Therapeutics Inc.
Martin has made over 5 trades of the Cara Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 10,800 units of CARA stock worth 111,024$ on 14 September 2022.
The largest trade he's ever made was buying 400,000 units of Cara Therapeutics Inc stock on 16 March 2016 worth over 1,948,000$. On average, Martin trades about 40,704 units every 196 days since 2014. As of 14 September 2022 he still owns at least 44,988 units of Cara Therapeutics Inc stock.
You can see the complete history of Mr. Vogelbaum stock trades at the bottom of the page.
Martin A. Vogelbaum serves as Lead Independent Director of the Company. Mr. Vogelbaum currently serves as Managing Partner of Inning One Ventures, a life science venture capital fund. Previously, Mr. Vogelbaum served as Corporate Vice President, Business Development at Celgene Corporation from 2015 to 2017. Mr. Vogelbaum served as a partner of Rho Ventures from 2005 until 2015 and again from 2017 to 2018, where he focused on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 25 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease. Mr. Vogelbaum previously served as a director of Inotek Pharmaceuticals Corporation (Nasdaq: ITEK) from 2010 to 2016 and NephroGenex, Inc. (Nasdaq: NRX) from 2013 to 2014. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation. Mr. Vogelbaum received his A.B. in biology and history from Columbia University. Mr. Vogelbaum’s experience in the life sciences industry as a venture capitalist provides him with the qualifications and skills to serve on our Board of Directors.
As the Lead Independent Director of Cara Therapeutics Inc, the total compensation of Martin Vogelbaum at Cara Therapeutics Inc is 352,524$. There are 9 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of 3,736,190$.
Martin Vogelbaum is 56, he's been the Lead Independent Director of Cara Therapeutics Inc since 2010. There are 7 older and 10 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Martin's mailing address filed with the SEC is Carnegie Hall, 152 W 57th St, New York, NY 10019, USA.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over 25,200,591$ worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth 19,406,983$ . The most active insiders traders include Edward Hurwitz、Martin Vogelbaum、Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of 5,343$. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth 1,452$.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: